Literature DB >> 10326891

DiHA Dextran Copolymer, a new biocompatible material for endoscopic treatment of stress incontinent women. Short term results.

A Stenberg1, G Larsson, P Johnson, G Heimer, U Ulmsten.   

Abstract

BACKGROUND: This study was undertaken to investigate the safety and effect of DiHA, dextranomers in hyaluronan, a new biocompatible material for endoscopic treatment of stress incontinence, and to further develop the injection technique.
METHODS: Twenty women aged 38 to 90 years with genuine stress incontinence participated. Seventeen were followed for a minimum of 6 months after treatment and three for a minimum of 3 months. The DiHA implants were administrered by transurethral endoscopically controlled submucosal injections under local anesthesia. Safety was assessed mainly in terms of infection, need for catheterization, residual urine and dysuria. The treatment efficacy was estimated objectively by a short-term pad test with standardized physical exercise and a 48 h pad-test, 7 days, and 1, 3 and 6 months after treatment. The patient's subjective experience of the effect was also studied.
RESULTS: The implantation procedure was well accepted by the patients. Four patients required catheterization due to voiding problems during the first 24 postoperative hours. One patient had urinary retention 14 days postoperatively. No UTI or local infection was detected. Some patients had transient urgency. In 17 or 20 patients the treatment resulted in objective cure or improvement.
CONCLUSIONS: This substance shows promising qualities for endoscopic treatment of stress incontinence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10326891

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  8 in total

1.  First paediatric experience of a new device for "non-endoscopic" periurethral injection in urinary incontinence.

Authors:  N Capozza; M De Dominicis; G Collura; P Caione
Journal:  Pediatr Surg Int       Date:  2005-10-20       Impact factor: 1.827

2.  Bulking agents in the treatment of stress urinary incontinence: history, outcomes, patient populations, and reimbursement profile.

Authors:  Lindsey A Kerr
Journal:  Rev Urol       Date:  2005

Review 3.  Treatment of stress urinary incontinence: recent developments in the role of urethral injection.

Authors:  Philip van Kerrebroeck; Flip ter Meulen; Elisabeth Farrelly; Gregor Larsson; Lena Edwall; Aino Fianu-Jonasson
Journal:  Urol Res       Date:  2003-01-30

4.  The tyrosine phosphorylation of Munc18c induces a switch in binding specificity from syntaxin 4 to Doc2beta.

Authors:  Jenna L Jewell; Eunjin Oh; Sara M Bennett; Samy O Meroueh; Debbie C Thurmond
Journal:  J Biol Chem       Date:  2008-06-09       Impact factor: 5.157

Review 5.  The endoscopic treatment of incontinence in children.

Authors:  Paolo Caione; Alberto Lais
Journal:  Curr Urol Rep       Date:  2002-04       Impact factor: 3.092

Review 6.  Treatment of urinary incontinence.

Authors:  E S Rovner
Journal:  Curr Urol Rep       Date:  2000-10       Impact factor: 3.092

7.  Urethral injection for stress urinary incontinence: long-term results with dextranomer/hyaluronic acid copolymer.

Authors:  A M Stenberg; G Larsson; P Johnson
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-09-13

Review 8.  Injectable agents: present and future.

Authors:  Deborah J Lightner; Nancy B Itano; Susan D Sweat; Kristin L Chrouser; Felecia Fick
Journal:  Curr Urol Rep       Date:  2002-10       Impact factor: 2.862

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.